NCT02245516View on ClinicalTrials.gov

Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Retinal Vein OcclusionDiabetic Macular Edema
Interventions
DRUG

KPI-121 0.25% Ophthalmic Suspension

KPI-121 drug product will be supplied a 0.25% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.

DRUG

KPI-121 1.0% Ophthalmic Suspension

KPI-121 drug product will be supplied a 1.0% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.

Trial Locations (2)

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

02114

Ophthalmic Consultants of Boston, Boston

Sponsors
All Listed Sponsors
lead

Kala Pharmaceuticals, Inc.

INDUSTRY

NCT02245516 - Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema | Biotech Hunter | Biotech Hunter